<h4>Background</h4>The expression of serine protease granzyme-B (GzmB) by circulating CD8<sup>+</sup> T lymphocytes has been recently suggested as a biomarker for poor immunotherapy response and severe disability in patients with Neuromyelitis Optica spectrum disorders (NMOSD). This evidence concerns the gene GZMB and neuromyelitis optica.